市場調査レポート
商品コード
1423334
病院感染病検査市場レポート:適応症別、地域別、2024年~2032年Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
病院感染病検査市場レポート:適応症別、地域別、2024年~2032年 |
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2~3営業日
|
世界の病院感染病検査市場規模は2023年に121億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに466億米ドルに達し、2024年から2032年の間に15.6%の成長率(CAGR)を示すと予測しています。
病院感染(HAI)または院内感染症は、病院や診療所で発症する疾患です。院内感染とは、病院内で発生する感染症や病気を意味します。特別養護老人ホーム、リハビリテーションセンター、病院、その他の臨床環境の近くでも、このような病気にかかる可能性があります。ほとんどの人は集中治療室(ICU)や救急治療室(ER)にいるときにHAIに感染します。一般的に、これらの疾患の潜伏期間は、患者が入院してから48時間から4日の間です。院内感染の主な原因は、病院内のスタッフが適切な衛生管理を行っていないことです。その他の理由としては、メンテナンスの不備、病院スタッフの自己満足、多剤耐性菌(MDRO)の増加などが挙げられます。最もよく発生する院内感染には、肺炎、一次血流感染、尿路感染などがあります。多くの場合、これらの院内感染症は患者自身のマイクロバイオームに起因することもあることがわかっています。感染症は、特に外科手術の後などに、皮膚保護層が脅威となりうるものと接触し、感染を引き起こすことで発生します。
人口の増加とヘルスケア・インフラの近代化により、世界中でヘルスケア施設の数が大幅に増加しています。その結果、HAIの発生率が上昇し、病院感染病検査の需要を牽引しています。さらに、高度な技術と科学的革新により、マイクロアレイ、ポリメラーゼ連鎖反応(PCR)、リアルタイム・ロケーション・システム(RTLS)、固相ハイブリダイゼーションなど、HAIの予防、診断、モニタリングのためのさまざまな技術が市場で利用できるようになった。RTLSのような技術は、患者とスタッフの両方にHAIの蔓延を防ぐことを容易にします。患者の間でのHAIに対する意識の高まりや、HAIの発生率が高い病院を罰する規制を制定する政府の動きは、市場の成長を促進するその他の要因の一部です。
The global hospital acquired disease testing market size reached US$ 12.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 46.6 Billion by 2032, exhibiting a growth rate (CAGR) of 15.6% during 2024-2032.
Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.
Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital acquired disease testing market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on indication.
UTI (Urinary Tract Infection)
SSI (Surgical Site Infection)
Pneumonia
Bloodstream Infections
MRSA (Methicillin-Resistant Staphylococcus Aureus)
Others
Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.